Format

Send to

Choose Destination
Clin Med Insights Gastroenterol. 2012 Jun 25;5:31-41. doi: 10.4137/CGast.S7382. eCollection 2012.

Rifaximin therapy of irritable bowel syndrome.

Author information

1
Baylor College of Medicine, Houston, TX. ; University of Texas at Houston School of Public Health, Houston, TX.
2
Baylor College of Medicine, Houston, TX.
3
Veterans Affairs Medical Center, East Orange, NJ.
4
Baylor College of Medicine, Houston, TX. ; University of Texas at Houston School of Public Health, Houston, TX. ; St. Luke's Episcopal Hospital.

Abstract

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal pain and altered bowel habits in the absence of specific organic pathology. Although the underlying pathogenesis of IBS is not well-understood, small intestinal bacterial overgrowth (SIBO) or other abnormalities in the gut flora is believed to contribute to the development of a subset of IBS cases. Rifaximin is a poorly absorbed antimicrobial with activity against enteric pathogens. A number of studies have shown a significant improvement in IBS symptoms with antibiotic therapy including rifaximin. In this review, we discuss the pharmacokinetics, in vitro susceptibility profile, and efficacy and safety data from clinical trials of rifaximin treatment of IBS.

KEYWORDS:

irritable bowel syndrome; rifaximin; small intestinal bacterial overgrowth

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center